Overview
Allena Pharmaceuticals is developing and commercializing non-systemic protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions.
Allena was founded in 2011 with $15 million in Series A venture capital financing led by top-tier venture investors Bessemer Venture Partners, Frazier Healthcare and Third Rock Ventures.
Based in Newton, Mass., Allena was co-founded by Alexey Margolin, Ph.D., and Robert Gallotto, industry leaders with a proven track record of success in protein therapeutic design and development. Allena is leveraging its leadership team’s combined operational expertise in manufacturing, formulation and non-systemic protein delivery.